drugset / Trial / NCT05098249

Ferric Carboxymaltose With or Without Phosphate Substitution for the Treatment of Iron Deficiency or Iron Deficiency Anemia

NCT05098249 ↗

Phase 4 Completed 92 enrolled Donat R. Spahn University of Zurich · collab
RandomizedParallel-groupTriple-blindTreatment

Summary

This is a confirmatory trial to establish superior serum phosphate stability associated with use of Phoscap® compared with placebo as a supplement for treatment of iron deficiency or iron deficiency anemia with Ferinject® before elective surgery.

Timeline

Start
2021-11-11
Primary completion
2023-05-09
Completion
2023-05-23

Outcome

Missed primary endpoint

paper 0.49 ± 0.21 mmol/L in the treatment group and 0.42 ± 0.17 mmol/L in the placebo group (p = 0.12, two-sided p-value). PMID 39671753 ↗

Drugs

EvaluationDrugModalityDoseRoute
Subject Phoscap® Unknown 6 mmol Oral